Vanda and Anaptys announce successful Phase 3 trials for imsidolimab, proceeding with regulatory applications for Generalized Pustular Psoriasis treatment.
Quiver AI Summary
Vanda Pharmaceuticals and AnaptysBio have announced a global license agreement for the development and commercialization of imsidolimab, an IL-36R antagonist that has completed two successful Phase 3 trials for Generalized Pustular Psoriasis (GPP). GPP is a severe, rare skin disorder caused by mutations in the IL36RN gene, leading to significant inflammation and potentially life-threatening symptoms. Vanda will prepare for U.S. and EU regulatory filings and commercialization of imsidolimab, providing Anaptys with a $10 million upfront payment, $5 million for existing drug supply, and up to $35 million in future milestones, plus a 10% royalty on global sales. The positive trial results indicate that imsidolimab could be a promising new treatment option for patients suffering from this debilitating disease.
Potential Positives
- Imsidolimab has successfully completed two global Phase 3 studies, demonstrating significant efficacy in treating Generalized Pustular Psoriasis (GPP), which is a rare and severe skin disease.
- Vanda Pharmaceuticals plans to immediately prepare BLA and MAA applications for the US and EU, indicating a robust pathway towards regulatory approval and potential commercialization in these major markets.
- AnaptysBio will receive $15 million from Vanda, providing immediate financial benefit and additional incentives tied to future regulatory approvals and sales milestones, enhancing the partnership's viability.
- Vanda is positioned to leverage its existing expertise in rare disease treatments and has a commercial portfolio that synergizes with imsidolimab, potentially accelerating its market entry and expanding treatment options for patients with inflammatory conditions.
Potential Negatives
- The press release highlights a significant financial commitment from Vanda to Anaptys, including an upfront payment of $10 million coupled with potential milestone payments, which may strain Vanda's financial resources depending on future revenues from imsidolimab.
- The mention of GPP's rarity and low prevalence may suggest limited market size for imsidolimab, potentially impacting its commercial success and return on investment.
- Vanda's reliance on Anaptys for a 10% royalty on global net sales indicates potential revenue sharing that could limit Vanda's profitability from this product, which could face additional pressures depending on its market acceptance and competitive landscape.
FAQ
What is imsidolimab and its purpose?
Imsidolimab is an IL-36R antagonist being developed to treat Generalized Pustular Psoriasis (GPP), a severe inflammatory skin condition.
What did the Phase 3 studies of imsidolimab demonstrate?
The Phase 3 studies showed that imsidolimab effectively cleared skin in GPP patients, with no significant safety concerns reported.
What is the significance of the BLA and MAA applications?
The BLA (Biologics License Application) and MAA (Marketing Authorization Application) are crucial for gaining regulatory approval to market imsidolimab in the US and EU.
How much will AnaptysBio receive from Vanda?
AnaptysBio will receive $15 million from Vanda, including a $10 million upfront payment and $5 million for existing drug supply.
What future plans does Vanda have for imsidolimab?
Vanda plans to initiate technology transfer and begin regulatory submissions for imsidolimab in 2025, aiming for commercialization soon after.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANAB Insider Trading Activity
$ANAB insiders have traded $ANAB stock on the open market 13 times in the past 6 months. Of those trades, 4 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 4 purchases buying 359,070 shares for an estimated $11,099,620 and 0 sales.
- ERIC J LOUMEAU (CHIEF LEGAL OFFICER) has made 0 purchases and 3 sales selling 12,500 shares for an estimated $492,460.
- DENNIS MULROY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 12,220 shares for an estimated $487,724.
- HOLLINGS RENTON sold 10,000 shares for an estimated $250,000
- PAUL F. LIZZUL (Chief Medical Officer) has made 0 purchases and 3 sales selling 5,720 shares for an estimated $224,429.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANAB Hedge Fund Activity
We have seen 92 institutional investors add shares of $ANAB stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 622,893 shares (+207.5%) to their portfolio in Q3 2024, for an estimated $20,866,915
- CAMBER CAPITAL MANAGEMENT LP removed 500,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $16,750,000
- FMR LLC added 438,557 shares (+15.3%) to their portfolio in Q3 2024, for an estimated $14,691,659
- BLACKROCK, INC. added 410,245 shares (+23.2%) to their portfolio in Q3 2024, for an estimated $13,743,207
- CORMORANT ASSET MANAGEMENT, LP added 342,465 shares (+inf%) to their portfolio in Q3 2024, for an estimated $11,472,577
- EVENTIDE ASSET MANAGEMENT, LLC removed 304,576 shares (-53.6%) from their portfolio in Q3 2024, for an estimated $10,203,296
- BALYASNY ASSET MANAGEMENT L.P. added 303,211 shares (+inf%) to their portfolio in Q3 2024, for an estimated $10,157,568
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
- Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis
- Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU
- Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply
-
Anaptys to receive a 10% royalty on global net sales of imsidolimab
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP).
GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines. Dysregulation of this balance in IL-36 signaling leads to severe chronic skin inflammation with pustules and systemic symptoms which carry significant morbidity and mortality often associated with sepsis and multi-organ failure. 1
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program in GPP, including the GEMINI-1 and GEMINI-2 global Phase 3 studies.
In 2025, Vanda intends to initiate and complete the technology transfer activities and will immediately begin preparing the BLA and MAA applications for the US and EU and making preparations for commercialization.
“We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this IL-36 signal regulator in the treatment of additional inflammatory conditions where the IL-36 homeostatic balance is dysregulated,” said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. “Imsidolimab has great synergy with our commercial portfolio, leveraging both our rare disease expertise in the US and EU as well as the anti-inflammatory portfolio that includes Ponvory ® for multiple sclerosis, psoriasis and ulcerative colitis.”
GPP prevalence estimates in the general population vary considerably, between 1.76 and 124 patients per million persons worldwide. 2 The majority of GPP cases are caused by genetic variants in IL36RN. 3,4 Loss-of-function mutations in IL36RN are mostly missense mutations in a recessive pattern and result in unrestricted IL-36 activity. 5,6
"GPP is a severely debilitating, life-threatening skin disease in need of novel therapeutic approaches,” said Johann Gudjonsson, M.D., Ph.D., Arthur C. Curtis Professor of Molecular Skin Immunology and Scholar of the Taubman Medical Research Institute, University of Michigan. "The positive Phase 3 data, demonstrating GPP patients achieved rapid disease clearance through Week 4 after a single dose of infused imsidolimab, and maintained clear to almost clear skin for at least 24 weeks, with no clinically meaningful safety signals, represents a promising new option for patients living with this disease. I’m excited imsidolimab is progressing toward a regulatory filing this year.”
"Vanda is an ideal partner for imsidolimab due to their strong regulatory and commercial capabilities in the US and Europe, evidenced by successful recent launches in specialty and rare diseases, and their commitment to invest in label expansion across their therapeutic portfolio, including their growing presence in inflammatory disease," said Daniel Faga, president and chief executive officer of Anaptys. “Following our productive pre-BLA meeting with FDA in 2024, we look forward to Vanda’s BLA and MAA submissions later in 2025, with the hope that this potentially differentiated therapeutic option will be made available for patients living with GPP, a burdensome, and sometimes life-threatening skin disease.”
Under the terms of the agreement, Vanda will make to Anaptys an upfront payment of $10 million and a $5 million payment for existing drug supply. Anaptys is also eligible to receive up to $35 million for future regulatory approval and sales milestones in addition to a 10% royalty on net sales. Vanda will receive an exclusive global license to develop, manufacture and commercialize imsidolimab.
Guggenheim Securities acted as financial advisor and Fenwick & West LLP served as legal counsel to Anaptys on this transaction. Cantor Fitzgerald & Co. acted as financial advisor and Orrick, Herrington & Sutcliffe LLP served as legal counsel to Vanda.
About GEMINI-1 and GEMINI-2 Studies
In the 45-patient GEMINI-1 Phase 3 trial, patients were randomized 1:1:1 to receive a single infusion of 750mg intravenous (IV) imsidolimab, 300mg IV imsidolimab or placebo at Day 0. Of the patients who received a single dose of 750mg IV imsidolimab, 53% achieved a GPP Physician Global Assessment (GPPPGA) score of 0/1 (clear or almost clear skin) at Week 4 (primary endpoint), compared to 13% of the patients on placebo (p=0.0131). Of the patients who received a single dose of 300mg IV imsidolimab, 53% achieved GPPPGA 0/1 at Week 4.
Sixteen GPPPGA 0/1 responder patients from GEMINI-1 were subsequently re-randomized to monthly maintenance dosing of either 200mg subcutaneous (SC) imsidolimab or placebo in the GEMINI-2 Phase 3 trial. Patients were followed for at least 24 weeks and up to a maximum of 92 weeks. Of the eight responding patients from GEMINI-1 who were re-randomized to monthly 200mg SC imsidolimab maintenance therapy, 100% maintained a GPPPGA score of 0/1 and none of them experienced a flare. Of the remaining eight responding patients from GEMINI-1 who were re-randomized to placebo, 25% maintained a GPPPGA score of 0/1 and 63% experienced a flare.
Data from both trials demonstrated a consistent, favorable safety and tolerability profile with no treatment-related serious adverse events (SAEs) or SAEs leading to discontinuation reported in imsidolimab-treated patients.
About Imsidolimab and GPP
Imsidolimab is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP. Regulatory and patent exclusivity is expected to extend into the late 2030s.
GPP is a rare, chronic, systemic autoinflammatory disease that is potentially life-threatening, if left untreated.
During a GPP flare, individuals experience the sudden eruption of painful pustules. These pustules appear over large areas of the skin, accompanied by redness, severe itchiness, and dry, cracked, or scaly skin. People with GPP may also experience more general symptoms such as fever, headache, extreme tiredness, or a burning sensation on the skin.
About Vanda Pharmaceuticals, Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist ( Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the anticipated timing of the preparation and submission of regulatory filings in the US and EU and the initiation and completion of technology transfer activities; Vanda’s plans with respect to its commercial launch activities; the estimated prevalence of GPP; the commercial availability of imsidolimab to treat patients with GPP; the potential for Anaptys to receive any royalties or milestone payments from the Vanda license agreement; and the potential for any patent life extension for imsidolimab. Statements including words such as “plan,” “intend,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause each company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to each company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize each of its product candidates, the timing and results of preclinical and clinical trials, each company’s ability to fund development activities and achieve development goals, each company’s ability to protect intellectual property, and the accuracy of the of the estimates of the number of patients with GPP worldwide, and other risks and uncertainties described under the heading “Risk Factors” in documents each of the companies files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and each of the companies undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Vanda Pharmaceuticals Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
202.734.3400
[email protected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]
Anaptys Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
References:
- Armstrong, A. W. et al. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation. J Am Acad Dermatol 90, 727–730 (2024).
- Prinz, J. C. et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. Journal of the European Academy of Dermatology and Venereology 37, 256–273 (2022).
- Marrakchi, S. et al. Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis. New England Journal of Medicine 365, 620–628 (2011).
- Sugiura, K. et al. The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist. Journal of Investigative Dermatology 133, 2514–2521 (2013).
- Lee, C.-C., Huang, Y.-H., Chi, C.-C., Chung, W.-H. & Chen, C.-B. Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics. Trends Immunol 46, 74–89 (2025).
- Sachen, K. L., Arnold Greving, C. N. & Towne, J. E. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine 156, 155897 (2022).